100427-00-7

Usage

General Description

The chemical "2,6-dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid methyl ester 2-chloroethyl ester" is a compound with a complex structure that includes a 1,4-dihydropyridine core with methyl and 2-chloroethyl ester functional groups. 2,6-dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid methyl ester 2-chloroethyl ester is commonly used as a calcium channel blocker in the treatment of hypertension and angina. It works by relaxing and dilating the blood vessels, which helps to lower blood pressure and improve blood flow. Additionally, the 2,3-dichlorophenyl group enhances the potency of the compound, making it more effective at blocking calcium channels. This chemical is an important therapeutic agent that has applications in the management of cardiovascular diseases.

Upstream product

• 21731-17-9 methyl 3-aminocrotonate 
• 130370-24-0 2-[1-(2,3-Dichloro-phenyl)-meth-(E)-ylidene]-3-oxo-butyric acid 2-chloro-ethyl ester 

Relevant academic research and scientific papers

Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6- dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenylpropylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4- dihydropyridines binding site labelled by 3H-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375- lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries.

Process for the preparation of 1,4-dihydropyridine derivatives

In the preparation of 1,4-dihydropyridine derivatives of formula (I), the improvement which comprises reacting a 2-haloethyl 2-benzylidene-3-oxobutanoate of formula (IV) with a 3-aminocrotonic acid ester of formula (V) in a reaction medium in the presence of a dehydrating agent. In the formulae R1, R2, R3 and X have the same meanings as defined in the claims.